Reversible ototoxic effect of azithromycin and clarithromycin on transiently evoked otoacoustic emissions in guinea pigs

Journal of Laryngology and Otology

Volumn 115, Issue 8, 2001, Pages 622-628

  Uzun, C ^a   Koten, M ^a   Adali, M K ^a   Yorulmaz, F ^a   Yagiz R ^a   Karasalihoglu A R ^a  

^a TRAKYA UNIVERSITY   (Turkey)

Author keywords

Adverse Effects; Antibiotics; Audiometry; Azithromycin; Cochlea; Macrolide

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COCHLEA; COCHLEA POTENTIAL; CONTROLLED STUDY; EVOKED OTOACOUSTIC EMISSION; GUINEA PIG; HAIR CELL; INNER EAR; NONHUMAN; OTOTOXICITY; STATISTICAL ANALYSIS;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; GUINEA PIGS; INJECTIONS, INTRAVENOUS; OTOACOUSTIC EMISSIONS, SPONTANEOUS;

EID: 0034903888     PISSN: 00222151     EISSN: None     Source Type: Journal    
DOI: 10.1258/0022215011908676     Document Type: Article

References (33)

1. Comparison of macrolide antibiotics
2. Adverse effect of macrolide antibacterials
3. Ototoxic liability of erythromycin and analogues
4. Transient perceptive deafness due to erythromycin lactobionate
5. Ototoxicity with azithromycin
6. Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus
7. Azithromycin-related ototoxicity in patients infected with human immunodeficiency virus
8. Relationship adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease
9. Azithromycin-induced hearing loss
10. Intravenous azithromycin-induced ototoxicity
11. Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS
12. Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome
13. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS
14. Clarithromycin with minocycline and clofazimine for Mycobacterium avium intracellulare complex lung disease in patients without the acquired immune deficiency syndrome
15. Irreversible sensorineural hearing loss due to erythromycin
16. Irreversible ototoxic effect of erythromycin
17. Ototoxic reaction to erythromycin
18. Otoacoustic emissions in otologic practice
19. Otoacoustic emissions: An approach for monitoring aminglycoside-induced otoxocity
20. The effect of furosemide on evoked otoacoustic emissions in guinea pigs
21. Detection of cochlear dysfunction by the measurement of transiently evoked otoacoustic emissions in guinea pigs with autoimmune-induced labyrinthitis
22. Inner ear concentrations and ototoxicity of different antibiotics in local and systemic application
23. Vancomycin- and erythromycin-induced hearing loss in humans
24. Ototoxicity of erythromycin in man: Electrophysiologic approach
25. Inhibitory effect of erythromycin on ion transport by stria vascularis and vestibular dark cells
26. Ototoxic effect of erythromycin on cochlear potentials in the guinea pig
27. Evoked otoacoustic emissions: A comparison between responses from humans and guinea pigs
28. Pharmacokinetics of azithromycin in rats and dogs
29. Intravenous clarithromycin
30. Erythromycin ototoxicity: Prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia
31. Pharmacokinetics and pharmacodynamics of newer macrolides
32. Overview of the tolerability profile of clarithromycin in preclinical and clinical trials